An experimental prime-boost regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice

AIDS Research and Human Retroviruses

Volumn 14, Issue 5, 1998, Pages 401-407

  Brühl, Peter ^a   Kerschbaum, Astrid ^a   Eibl, Martha M ^b   Mannhalter, Josef W ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; GLYCOPROTEIN GP 160; IMMUNOSTIMULATING AGENT; RECOMBINANT VACCINIA VIRUS VSC25; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOSTIMULATION; INTRAGASTRIC DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS IMMUNITY; VIRUS RECOMBINATION;

EID: 0032549622     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.401     Document Type: Article

References (47)

1. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, and Ho DD: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (London) 1997;387:188-191.
2. Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M, Cort S, and Sullivan JL: Combination treatment with zidovudine, didanosine and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997; 336:1343-1349.
3. Poignard P, Klasse PJ, and Sattentau QJ: Antibody neutralization of HIV-1. Immunol Today 1996;17:239-246.
4. Ada GL and McElrath MJ: HIV type 1 vaccine-induced cytotoxic T cell responses: Potential role in vaccine efficacy. AIDS Res Hum Retroviruses 1997;13:205-210.
5. Cohen J: Looking for leads in HIV's battle with immune system. Science 1997;276:1196-1197.
6. Mestecky J and Jackson S: Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines. J Clin Immunol 1994;14: 259-272.
7. Belshe RB, Clements ML, Dolin R, Graham BS, McElrath J, Gorse GJ, Schwartz D, Keefer MC, Wright P, Corey L, Bolognesi DP, Matthews TJ, Stablein DM, O'Brien FS, Eibl M, Dorner F, and Koff W: Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type-1 vaccine in subjects at low risk of infection. J Infect Dis 1993;168: 1387-1395.
8. Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, Fast PE, Wright PF, Dolin R, Corey L, Belshe RB, Clements ML, Bolognesi DP, Stablein DM, Chernoff D, Duliege AM, and Walker CM: Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120 - a randomized, double-blind trial. Ann Intern Med 1996;125:270.
9. Niedrig M, Gregersen J-P, Fultz PN, Bröker M, Mehdi S, and Hilfenhaus J: Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), three different adjuvants and challenge. Vaccine 1993;11:67-74.
10. Race E, Frezza P, Stephens DM, Davis D, Polyanskaya N, Cranage M, and Oxford JS: An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses. Vaccine 1995;13:54-60.
11. Perkus ME, Tartaglia J, and Paoletti E: Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukocyte Biol 1995;58:1-13.
12. Hu S-L, Klaniecki J, Dykers T, Sridhar P, and Travis BM: Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160. AIDS Res Hum Retroviruses 1991;7:615-620.
13. Fleury B, Janvier G, Pialoux G, Buseyne F, Robertson MN, Tartaglia J, Paoletti E, Kieny MP, Excler JL, and Rivière Y: Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996;174:734-738.
14. Pialoux G, Excler JL, Rivière Y, Gonzalez-Canali G, Feuillie V, Coulaud P, Gluckman J-C, Matthews TJ, Meignier B, Kieny MP, Gonnet P, Diaz I, Méric C, Paoletti E, Tartaglia J, Salomon H, Plotkin S, and the Agis Group: A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retroviruses 1995;11: 373-381.
15. Perales M-A, Schwartz DH, Fabry JA, and Lieberman J: A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J Acquir Immune Defic Syndr Hum Retroviruses 1995;10:27-35.
16. Robinson HL, Lu S, Feltquate DM, Torres CT, Richmond J, Boyle CM, Morin MJ, Santoro JC, Webster RG, Montefiori D, Yasutomi Y, Letvin NL, Manson K, Wyand M, and Haynes JR: DNA vaccines. AIDS Res Hum Retroviruses 1996;12:455-457.
17. Ulmer JB, Sadoff JC, and Liu MA: DNA vaccines. Curr Opin Immunol 1996;8:531-536.
18. Walker RI: New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994;12:387-400.
19. Chakrabarti S, Robert-Guroff M, Wong-Staal F, Gallo RC, and Moss B: Expressing of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature (London) 1986;320:535-537.
20. Barrett N, Mitterer A, Mundt W, Eibl J, Eibl M, Gallo RC, Moss B, and Dorner F: Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. AIDS Res Hum Retroviruses 1989;5:159-171.
21. Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, Cornette JL, DeLisi C, Moss B, Germain RN, and Berzofsky JA: An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1988; 85:3105-3109.
22. Shirai M, Pendleton CD, and Berzofsky JA: Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules. J Immunol 1992; 148:1657-1667.
23. Ruedl C, Albin B, Böck G, Wick G, and Wolf H: Oral administration of a bacterial immunomodulator enhances murine intestinal lamina propria and Peyer's patch lymphocyte traffic to the lung: Possible implications for infectious disease prophylaxis and therapy. Int Immunol 1993;5:29-36.
24. Beagley KW, Eldridge JH, Kiyono H, Everson MP, Koopman WJ, Hojo T, and McGhee JR: Recombinant murine IL-5 induces high rate IgA synthesis in cycling IgA-positive Peyer's patch B cells. J Immunol 1988;141:2035-2042.
25. Jonjic S, DelVal M, Keil GM, Reddehase MJ, and Koszinowski UH: A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J Virol 1988;62:1653-1658.
26. McDermott MR and Bienenstock J: Evidence for a common mucosal immunology system. I. Migration of B immunoblasts into intestinal, respiratory and genital tissues. J Immunol 1979;122: 1892-1895.
27. Etchart N, Wild F, and Kaiserlian D: Mucosal and systemic immune responses to measles virus haemagglutinin in mice with a recombinant vaccinia virus. J Gen Virol 1996;77:2471-2478.
28. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, and Kiyono H: The mucosal immune system: From fundamental concepts to vaccine development. Vaccine 1992;10:75-88.
29. Bowen JC, Nair SK, Reddy R, and Rouse BT: Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. Immunology 1994;81: 338-342.
30. Bender BS, Rowe CA, Taylor SF, Wyatt LS, Moss B, and Small PA Jr: Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 1996;70: 6418-6424.
31. Meitin CA, Bender BS, and Small PA Jr: Enteric immunization of mice against influenza with recombinant vaccinia. Proc Natl Acad Sci USA 1994;91:11187-11191.
32. Cooney EL, McElrath MJ, Corey L, Hu S-L, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, and Greenberg PD: Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993;90: 1882-1886.
33. Tamura S, Asanuma H, Tomita T, Komase K, Kawahara K, Danbara H, Hattori N, Watanabe K, Suzuki Y, Nagamine T, Aizawa C, Oya A, and Kurata T: Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine 1994;12: 1083-1089.
34. Douce G, Turcotte C, Cropley I, Roberts M, Pizza M, Domenghini M, Rappuoli R, and Dougan G: Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci USA 1995;92: 1644-1648.
35. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet J-C, Cox WI, Davis SW, van der Hoeven J, Meignier B, Riviere M, Languet B, and Paoletto E: NYVAC: A highly attenuated strain of vaccinia virus. Virology 1992;188:217-232.
36. Guillaume JC: Vaccinia from recombinant virus expressing HIV genes. Lancet 1991;337:1034-1035.
37. Sutter G, Wyatt LS, Foley PL, Bennink JR, and Moss B: A recombinant vector derived from the hostrange-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994;12:1032-1040.
38. Radaelli A and De Giuli Morghen C: Expression of HIV-1 envelope gene by recombinant avipox viruses. Vaccine 1994;12:1101-1109.
39. Ramsay AJ, Husband AJ, Ramshaw IA, Bao S, Matthaei KI, Koehler G, and Kopf M: The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994;264:561-563.
40. Geissler M, Gesien A, Tokushige K, and Wands JR: Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997;158:1231-1237.
41. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B, Boyer JD, and Weiner DB: In vivo engineering of a cellular immune response by coadministration of IL-12 expressing vector with a DNA immunogen. J Immunol 1997;158:816-826.
42. Muster T, Ferko B, Klima A, Purtscher M, Trkola A, Schulz P, Grassauer A, Engelhardt OG, Garcia-Sástre A, Palese P, and Katinger H: Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J Virol 1995;69:6678-6686.
43. de Haan A, Renegar KB, Small PA Jr, and Wilschut J: Induction of a secretory IgA response in the murine female urogenital tract by immunization of the lungs with liposome-supplemented viral subunit antigen. Vaccine 1995;13:613-616.
44. Gorse GJ, Schwartz DH, Graham BS, Matthews TJ, Stablein DM, Frey SE, Belshe RB, Clements ML, Wright PF, Eibl M, and Fast PE: HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immunol 1994;98:178-184.
45. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, and Burke DS: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-348.
46. Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, Weinhold K, Bolognesi DP, Sposto R, Stablein DM, Twadell T, Berman PW, Gregory T, Izu AE, Walker MC, and Fast P: Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994;272:475-480.
47. Goldstein G: HIV-1 Tat protein as a potential AIDS vaccine. Nature Med 1996;2:960-964.